Antifosfolipid, Antikardiyolipin, Ekstrakte Edilebilen Nükleer Antijen ve Anti-Çift Sarmal Dna Antikorlarının Pozitif Olmasının Gebelik Sonuçları Üzerine Etkisi
xmlui.mirage2.itemSummaryView.MetaDataShow full item record
Tanacan A, Impact of Extractable Nuclear Antigen, Anti-Double Stranded DNA, Antiphospholipid Antibody, and Anticardiolipin Antibody Positivity on Obstetrical Complications and Pregnancy Outcomes, Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Perinatology, Fellowship Thesis, Ankara, 2019. Extractable nuclear antigen (ENA) and anti-double stranded DNA (anti-dsDNA) positivity and related diseases like systemic lupus erythematosus, Sjögren syndrome, and other autoimmune diseases are known to be associated with obstetrical complications and poor perinatal outcomes. The aim of this fellowship thesis is to demonstrate the importance of ENA, anti-dsDNA, antiphospholipid (APL), and anticardiolipin (ACL) antibody positivity on pregnancy outcomes. Ninety one pregnant women with known ENA, anti-dsDNA, APL IgG and IgM, or ACL IgG and IgM antibody positivity were retrospectively compared with 91 randomly selected pregnant woman in terms of obstetrical complications and pregnancy outcomes. Beksac Obstetrics Index-pregnancy (BOIp), calculated as (number of children + (π/10))/gravidity in the current pregnancy, was used to compare the risk level between groups. Significant differences were found in the median maternal age, gravidity, number of previous miscarriages, and BOIp between the groups (p = 0.04, p < 0.001, p < 0.001, and p < 0.001, respectively). Significant differences were also found between the study and control groups in the median gestational age at birth, birth weight, and APGAR1 score (p < 0.001 for all). Similarly, significant differences were found between groups in the rates of intra-uterine growth restriction, oligohydramnios, and gestational hypertension (p < 0.001, p = 0.05, and p = 0.05, respectively). There were 3 (3.3%) stillbirths in the study group and none in the control group (p = 0.123). We demonstrated that anti-dsDNA, ENA, APL, and ACL antibody positivity may cause immunologic inflammation at placenta and thereby affect pregnancy outcomes. Keywords: Pregnancy, extractable nuclear antigen, anti-double stranded DNA, antiphospholipid antibody, anticardiolipin antibody, perinatal morbidity and mortality, placental inflammation
xmlui.dri2xhtml.METS-1.0.item-citationKAYNAKLAR 1. Mecacci F, Pieralli A, Bianchi B, Paidas MJ, editors. The impact of autoimmune disorders and adverse pregnancy outcome. Seminars in perinatology; 2007: Elsevier. 2. Deguchi M, Yamada H, Sugiura-Ogasawara M, Morikawa M, Fujita D, Miki A, et al. Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: A multicenter study. Journal of reproductive immunology. 2017;122:21-7. 3. Scheres LJ, Marijnen MC, Middeldorp S. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. The Cochrane Library. 2017. 4. Beksaç K, Örgül G, Çağan M, Karaağaoğlu E, Arslan S, Beksaç MS. Retrospective evaluation of pregnant women with celiac disease. Journal of the Turkish German Gynecological Association. 2017;18(1):56. 5. Beksac K, Orgul G, Can GS, Oktem A, Kav T, Beksac MS. Management of Inflammatory Bowel Disease and Pregnancy using Prophylactic Low Dose Low Molecular Weight Heparin and Corticosteroids. Journal of Clinical & Diagnostic Research. 2017;11(11). 6. Orgul G, Aktoz F, Beksac MS. Behcet’s disease and pregnancy: what to expect? Journal of Obstetrics and Gynaecology. 2017:1-4. 7. Orgul G, Ozkan EU, Celik HT, Beksac MS. Autoimmune hepatitis and pregnancy: report of two cases with different maternal outcomes. Clinical and experimental hepatology. 2017;3(4):212. 8. Phan TG, Wong RC, Adelstein S. Autoantibodies to extractable nuclear antigens: making detection and interpretation more meaningful. Clinical and diagnostic laboratory immunology. 2002;9(1):1-7. 9. Fu SM, Dai C, Zhao Z, Gaskin F. Anti-dsDNA Antibodies are one of the many autoantibodies in systemic lupus erythematosus. F1000Research. 2015;4(F1000 Faculty Rev):939. 10. Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. American journal of hematology. 2012;87(S1):S75-S81. 11. Harris E, Boey M, Mackworth-Young C, Gharavi A, Patel B, Loizou S, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. The Lancet. 1983;322(8361):1211-4. 12. Lim W. Antiphospholipid syndrome. Hematology American Society of Hematology Education Program. 2013;2013:675-80. 13. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of thrombosis and haemostasis : JTH. 2006;4(2):295-306. 14. Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The implications of autoimmunity and pregnancy. Journal of autoimmunity. 2010;34(3):J287-J99. 15. Carp HJ, Selmi C, Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. Journal of autoimmunity. 2012;38(2-3):J266-J74. 16. Esplin MS, Branch DW, Silver R, Stagnaro-Green A. Thyroid autoantibodies are not associated with recurrent pregnancy loss. American journal of obstetrics and gynecology. 1998;179(6):1583-6. 17. Iijima T, Tada H, Hidaka Y, Mitsuda N, Murata Y, Amino N. Effects of autoantibodies on the course of pregnancy and fetal growth. Obstetrics & Gynecology. 1997;90(3):364-9. 18. Wiersinga W. Thyroid autoimmunity and miscarriage. Eur J Endocrinol. 2004;150:751-5. 19. Faden D, Tincani A, Tanzi P, Spatola L, Lojacono A, Tarantini M, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-β2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. European Journal of Obstetrics & Gynecology and Reproductive Biology. 1997;73(1):37-42. 20. Dreyfus M, Hedelin G, Kutnahorsky R, Lehmann M, Viville B, Langer B, et al. Antiphospholipid antibodies and preeclampsia: a case-control study. Obstetrics & Gynecology. 2001;97(1):29-34. 21. Xia Y, Kellems RE. Is preeclampsia an autoimmune disease? Clinical Immunology. 2009;133(1):1-12. 22. Stagnaro-Green A. Maternal thyroid disease and preterm delivery. The Journal of Clinical Endocrinology & Metabolism. 2009;94(1):21-5. 23. Huong D, Wechsler B, Bletry O, Vauthier-Brouzes D, Lefebvre G, Piette J-C. A study of 75 pregnancies in patients with antiphospholipid syndrome. The Journal of rheumatology. 2001;28(9):2025-30. 24. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. Journal of autoimmunity. 2009;33(2):92-8. 25. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstetrics & Gynecology. 2003;101(6):1333-44. 26. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. American journal of obstetrics and gynecology. 2008;199(2):127. e1-. e6. 27. Dhar JP, Essenmacher LM, Ager JW, Sokol RJ. Pregnancy outcomes before and after a diagnosis of systemic lupus erythematosus. American journal of obstetrics and gynecology. 2005;193(4):1444-55. 28. Beksaç MS, Aydın E, Tuğral M, Karaağaoğlu E. An Obstetrics Index for the Assessment of Risk Levels of “High Risk Pregnancy” Groups. Gynecology Obstetrics & Reproductive Medicine. 2016;21(1). 29. Shulman HB, Gilbert BC, Lansky A. The Pregnancy Risk Assessment Monitoring System (PRAMS): current methods and evaluation of 2001 response rates. Public Health Reports. 2006;121(1):74-83. 30. Robbins CL, Zapata LB, Farr SL, Kroelinger CD, Morrow B, Ahluwalia I, et al. Core state preconception health indicators—pregnancy risk assessment monitoring system and behavioral risk factor surveillance system, 2009. Morbidity and Mortality Weekly Report: Surveillance Summaries. 2014;63(3):1-62. 31. Beksac MS, Yurter H, Tanacan A, Soyak B, Orgul G, Hakli DA, et al. Gestational outcomes of pregnant women who have had invasive prenatal testing for the prenatal diagnosis of spinal muscular atrophy. South African Journal of Obstetrics and Gynaecology. 2018;24(1):12-4. 32. Turgal M, Gumruk F, Karaagaoglu E, Beksac MS. Methylenetetrahydrofolate reductase polymorphisms and pregnancy outcome. Geburtshilfe und Frauenheilkunde. 2018;78(09):871-8. 33. Beksaç K, Aktoz F, Örgül G, Çelik HT, Özgü-Erdinç AS, Beksaç MS. Pregnancy in papillary thyroid cancer survivors. Journal of the Turkish German Gynecological Association. 2018;19(2):94. 34. Fadiloglu E, Unal C, Beksac MS. Management and the pregnancy outcomes of patients positive for anti-parietal cell antibody. Human antibodies. 2018(Preprint):1-6. 35. Mumusoglu S, Beksac MS, Ekiz A, Ozdemir P, Hascelik G. Does the presence of autoantibodies without autoimmune diseases and hereditary thrombophilia have an effect on recurrent pregnancy loss? The Journal of Maternal-Fetal & Neonatal Medicine. 2016;29(14):2352-7. 36. Strauss III JF, Romero R, Gomez-Lopez N, Haymond-Thornburg H, Modi BP, Teves ME, et al. Spontaneous preterm birth: advances toward the discovery of genetic predisposition. American journal of obstetrics and gynecology. 2018;218(3):294-314. e2. 37. Figueras F, Caradeux J, Crispi F, Eixarch E, Peguero A, Gratacos E. Diagnosis and surveillance of late-onset fetal growth restriction. American journal of obstetrics and gynecology. 2018;218(2):S790-S802. e1. 38. Friedman P, Ogunyemi D. Oligohydramnios. Obstetric Imaging: Fetal Diagnosis and Care: Elsevier; 2018. p. 511-5. e1. 39. Practice Bulletin No. 180: Gestational Diabetes Mellitus. Obstetrics and gynecology. 2017;130(1):e17-e37. 40. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstetrics and gynecology. 2019;133(1):e1-e25. 41. PrabhuDas M, Bonney E, Caron K, Dey S, Erlebacher A, Fazleabas A, et al. Immune mechanisms at the maternal-fetal interface: perspectives and challenges. Nature immunology. 2015;16(4):328. 42. Moffett A, Chazara O, Colucci F. Maternal allo-recognition of the fetus. Fertility and sterility. 2017;107(6):1269-72. 43. Tanacan A, Unal C, Yucesoy HM, Duru SA, Beksac MS. Management and evaluation of pregnant women with Takayasu arteritis. Archives of gynecology and obstetrics. 2019;299(1):79-88. 44. Tanacan E, Tanacan A, Fadiloglu E, Unal C, Beksac MS. Psoriasis and Pregnancy: Retrospective Evaluation of 47 Pregnancies in a Tertiary Center. Gynecology Obstetrics & Reproductive Medicine. 2018:1-5. 45. Gerard C. 10 workshops on Immunology of preeclampsia. Journal of reproductive immunology. 2017;123:94-9. 46. Huppertz B, Weiss G, Moser G. Trophoblast invasion and oxygenation of the placenta: measurements versus presumptions. Journal of Reproductive Immunology. 2014;101:74-9. 47. Abrahams V. Novel mechanisms of placental inflammation in obstetric antiphospholipid syndrome. Placenta. 2017;57:243. 48. Challis JR, Lockwood CJ, Myatt L, Norman JE, Strauss III JF, Petraglia F. Inflammation and pregnancy. Reproductive sciences. 2009;16(2):206-15. 49. Kim MY, Guerra MM, Kaplowitz E, Laskin CA, Petri M, Branch DW, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Annals of the Rheumatic Diseases. 2018:annrheumdis-2017-212224. 50. Ma W-T, Chang C, Gershwin ME, Lian Z-X. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: a comprehensive review. Journal of autoimmunity. 2017;83:95-112. 51. Isenberg D, Manson J, Ehrenstein M, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey's end? 2007. 52. Rekvig O. Anti‐dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. Clinical & Experimental Immunology. 2015;179(1):5-10. 53. Borella E, Lojacono A, Gatto M, Andreoli L, Taglietti M, Iaccarino L, et al. Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunologic research. 2014;60(2-3):170-6. 54. Yaniv G, Twig G, Shor DB-A, Furer A, Sherer Y, Mozes O, et al. A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmunity reviews. 2015;14(1):75-9. 55. Damoiseaux J, Tervaert JC. From ANA to ENA: how to proceed? Autoimmunity reviews. 2006;5(1):10-7. 56. Tani C, Carli L, Vagnani S, Talarico R, Baldini C, Mosca M, et al. The diagnosis and classification of mixed connective tissue disease. Journal of autoimmunity. 2014;48:46-9. 57. Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Current opinion in rheumatology. 2014;26(2):118-23. 58. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nature Reviews Rheumatology. 2011;7(6):330. 59. Comarmond C, Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmunity Reviews. 2013;12(7):752-7. 60. Ozyuncu O, Tanacan A, Aktoz F, Buyukeren M, Karabudak R, Beksac MS. Gestational outcomes of patients with multiple sclerosis: A tertiary centre experience. South African Journal of Obstetrics and Gynaecology. 2018;24(3). 61. Young E. The anti-inflammatory effects of heparin and related compounds. Thrombosis research. 2008;122(6):743-52.
The following license files are associated with this item: